The British Society for Rheumatology Biologics Register: 6 years on
about
Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterRisk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general populationCorrelation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study SRisk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activityThe incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and GenomiAnti-TNF-alpha therapy with infliximab in spondyloarthritides.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study.Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterBiologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
P2860
Q34395306-59F79157-D34F-4B35-8EA0-02F71A7DA013Q34672043-6B8BAC2A-982D-431C-8E11-0EC2E9C0062FQ34699641-9328671A-3141-4693-B5F0-5F69BA70BBE2Q35200349-C763D2D5-0445-4407-9AD8-4E4E756DBE5AQ35200354-43C533E6-0FDA-4C54-8373-F312F187D6EEQ36464357-6F32193D-8623-467B-A6E5-3C26E5506EDCQ36633196-DECF16D1-3D2D-4391-B228-C8C5E7D4DFE9Q36679750-0B87C8E3-9247-45D0-BDAD-B23558D8B465Q37347655-F1192F55-E72B-403E-ADCE-25586E606759Q37383424-29C9CA7A-2A6B-4644-BA97-A4517D9920EAQ37650221-3FAF8A18-28F0-4785-820D-D2BA52E97C6AQ37662605-6008042E-3A41-4F1C-8F54-74C92A77F423Q37729028-9656258F-94C8-4261-A8E4-C18BDF1AA509Q38207759-83E44497-0F96-4031-9B45-89C38474722AQ39710704-08E4D0A6-163D-45C0-818F-5D28F0711314Q40386790-CB767661-C047-48C1-89C2-5021F0599292Q44567719-94051C5E-7CD7-414F-A126-46585EFCDC79Q47687376-E5764249-F44C-400A-9D3A-D2F906D6BAC3Q47883430-1EF7509E-9495-4A6F-B2BD-4823DF66B467Q51019088-0EF62646-B020-49B0-9731-3BECDB30197DQ52887542-14A3EB50-0486-4C04-9090-3864C6D9E575Q56969693-DBE99E2E-A8B4-453E-A79C-2BF4B0EA171BQ56975651-1883CE76-354E-4A52-BBBF-22908279C642
P2860
The British Society for Rheumatology Biologics Register: 6 years on
description
im Juli 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 July 2008
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2008
@uk
name
The British Society for Rheumatology Biologics Register: 6 years on
@en
The British Society for Rheumatology Biologics Register: 6 years on
@nl
type
label
The British Society for Rheumatology Biologics Register: 6 years on
@en
The British Society for Rheumatology Biologics Register: 6 years on
@nl
prefLabel
The British Society for Rheumatology Biologics Register: 6 years on
@en
The British Society for Rheumatology Biologics Register: 6 years on
@nl
P2093
P2860
P356
P1433
P1476
The British Society for Rheumatology Biologics Register: 6 years on
@en
P2093
BSR Biologics Register
K D Watson
K L Hyrich
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEN242
P577
2008-07-01T00:00:00Z